The vaccine manufactured by Zydus Cadila’s vaccine ZyCov-D will be approved this week. After the third testing phase, Zydus Cadila submitted for an Emergency Use Authorization (EUA) for ZyCoV-D on July 1. The Ahmedabad-based business, which created the world’s first DNA COVID-19 vaccine, plans to market it to youngsters aged 12 and up, making it India’s first vaccination aimed at inoculating teenagers. The vaccine’s effectiveness in the intermediate phase was 66.6 percent.
So far, the Government has authorized five Covid vaccines: Covishield, Covaxin, Sputnik V, Moderna, and Johnson & Johnson single-dose vaccination. Zydus Cadila stated in a statement last month that ‘ZyCoV-D’ will be a three-dose vaccination with a production capacity of 10-12 crore doses per year. The pharma giant went on to say that it has undertaken India’s most extensive Covid vaccination study, which included 50 testing centers.
Read also: Zydus Cadila’s DNA Covid vaccine ready, sought approval for emergency use
How is ZyCoV-D different?
ZyCov-D is a DNA vaccination based on plasmid DNA, which is a tiny, circular, extrachromosomal bacterial DNA, according to the company’s website. The genetic code of the virus is carried by plasmid DNA, which can self-replicate. This aids in the production of spike protein and the development of antibodies by the plasmids. ZyCoV-D is a three-dose vaccination administered at 28-day intervals. Zydus Cadila makes ZyCoV-D in cooperation with the National Biopharma Mission of the Centre.
Phase-3 clinical studies were done on 30,000 healthy adult volunteers, according to the company’s website, and the drug was proven to be safe, well-tolerated, and immunogenic. The vaccine was proven safe and generated a high immunogenic response in phase-1/2 studies, which involved 1000 participants. The vaccine has been tested in over 60 locations and is stable at temperatures ranging from 2 to 8 degrees.
Read also: Statutory nod for Zydus Cadila vax for 12-18 age-group soon, Centre to HC
Furthermore, Zydus Cadila CEO Dr. Sharvil Patel stated that the vaccine is administered without needles. The vaccination container includes a spring-powered mechanism that injects the injection into the recipient in a precise stream. By December 2021, Zydus plans to generate five crore doses. According to Dr. Patel, two doses of ZyCoV-D should be enough to avoid COVID-19-related hospitalization. Genova’s mRNA vaccine, Biological E’s Corbevax, Covaxin’s nasal vaccine, and Novovax’s Covovax are developed vaccines.
